96 Tests PN: B113299

Components:

45x Ab-conjugated beads (S5P12 - human sVEGFR2 Ab-bead). PN: B113299A. One vial containing 100 µL of anti-human sVEGFR2 conjugated to AimPlex Bead S5P12.

25x Biotin-detection Ab (human sVEGFR2 Biotin-dAb). PN: B113299B. One vial containing 100 µL of biotinylated anti-human sVEGFR2.

Lyophilized Standard Mix-Human Group 5 Panel A, 8-Plex. PN: HG50008. One vial containing lyophilized recombinant human sE-Cadherin, sLIGHT, sTRAIL-R3, s4-1BB, sCD30L, sVEGFR2, BlyS, and sPECAM-1. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

Application: Optimal antibody pair and antigen standard for assaying human VEGFR2/Flk-1/sCD309/KDR. Can be multiplexed with other analytes in Human Group 5.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 5 pg/mL

  • Quantitation range:

  • LLOQ: < 10 pg/mL

  • ULOQ: > 5,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity of analytes in Human Group 5: Negligible

  • Sample volume: 15 µL/test

Description:

Kinase insert Domain Receptor (KDR), a type III receptor tyrosine kinase, also known as Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) is a VEGF receptor. It has also been designated as CD309. KDR is also known as Fetal Liver Kinase 1 (Flk-1). VEGF R2 (KDR/Flk-1), VEGF R1 (Flt-1) and VEGF R3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGF R1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis. Diseases associated with KDR include hemangioma, capillary infantile and familial capillary hemangioma. 

References:

  1. Holmes K, Roberts OL, Thomas AM, Cross MJ. (October 2007). "Vascular endothelial growth factor receptor-2: structure, function, intracellular signaling and therapeutic inhibition". Cell Signal. 19 (10): 2003–2012. doi:10.1016/j.cellsig.2007.05.013. PMID 17658244.

  2. Petrova TV, Makinen T, Alitalo K (1999). "Signaling via vascular endothelial growth factor receptors". Exp. Cell Res. 253 (1): 117–30. doi:10.1006/excr.1999.4707. PMID 10579917.

  3. Wang J, Fu X, Jiang C, Yu L, Wang M, Han W, Liu L, Wang J. (2014). "Bone marrow mononuclear cell transplantation promotes therapeutic angiogenesis via upregulation of the VEGF-VEGFR2 signaling pathway in a rat model of vascular dementia". Behav Brain Res. 265: 171–180. doi:10.1016/j.bbr.2014.02.033. PMC 4000455. PMID 24589546.